Here's Why Telix Pharmaceuticals (ASX:TLX) Can Manage Its Debt Responsibly
May 15
Have your own idea? Try our Stock Screener
Australian (ASX) Biotech Industry Analysis
UpdatedMay 26, 2025
DataAggregated Company Financials
Companies31
- 7D1.4%
- 3M-7.2%
- 1Y-9.1%
- YTDn/a
In the last week, the Biotech industry is up 1.4%, with CSL up 1.9%. However, the industry is down 9.1% over the past year. Looking forward, earnings are forecast to grow by 15% annually.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 26 May 2025 | AU$133.4b | AU$24.5b | AU$3.9b | 21x | 34.5x | 5.4x |
| Wed, 23 Apr 2025 | AU$128.0b | AU$24.8b | AU$3.9b | 20.2x | 32.6x | 5.2x |
| Fri, 21 Mar 2025 | AU$138.8b | AU$25.3b | AU$4.0b | 21.8x | 34.7x | 5.5x |
| Sun, 16 Feb 2025 | AU$140.8b | AU$24.9b | AU$3.8b | 22.9x | 37.3x | 5.7x |
| Tue, 14 Jan 2025 | AU$150.4b | AU$25.0b | AU$3.7b | 23.6x | 40.1x | 6x |
| Thu, 12 Dec 2024 | AU$149.0b | AU$24.2b | AU$3.6b | 25.1x | 41.2x | 6.2x |
| Sat, 09 Nov 2024 | AU$151.2b | AU$23.2b | AU$3.4b | 26.9x | 43.9x | 6.5x |
| Mon, 07 Oct 2024 | AU$152.1b | AU$22.7b | AU$3.3b | 27.9x | 45.4x | 6.7x |
| Wed, 04 Sep 2024 | AU$159.0b | AU$22.9b | AU$3.4b | 29.7x | 47x | 6.9x |
| Fri, 02 Aug 2024 | AU$161.2b | AU$22.6b | AU$3.3b | 32.2x | 48.5x | 7.1x |
| Sun, 30 Jun 2024 | AU$153.7b | AU$22.1b | AU$3.2b | 32x | 47.4x | 6.9x |
| Tue, 28 May 2024 | AU$145.9b | AU$22.1b | AU$3.2b | 31.2x | 45.2x | 6.6x |
| Thu, 25 Apr 2024 | AU$144.0b | AU$22.6b | AU$3.3b | 30.1x | 43.5x | 6.4x |
| Sat, 23 Mar 2024 | AU$143.7b | AU$22.5b | AU$3.3b | 29.4x | 43.5x | 6.4x |
| Mon, 19 Feb 2024 | AU$144.5b | AU$22.3b | AU$3.3b | 31x | 44x | 6.5x |
| Wed, 17 Jan 2024 | AU$144.9b | AU$20.8b | AU$2.8b | 33.3x | 52.6x | 7x |
| Fri, 15 Dec 2023 | AU$138.5b | AU$20.4b | AU$2.7b | 34.5x | 51.3x | 6.8x |
| Sun, 12 Nov 2023 | AU$128.5b | AU$21.5b | AU$2.9b | 30.2x | 44.6x | 6x |
| Tue, 10 Oct 2023 | AU$129.8b | AU$21.6b | AU$2.8b | 30x | 45.7x | 6x |
| Thu, 07 Sep 2023 | AU$138.6b | AU$21.5b | AU$2.8b | 33x | 49.2x | 6.4x |
| Sat, 05 Aug 2023 | AU$136.2b | AU$18.4b | AU$2.4b | 36.3x | 57.2x | 7.4x |
| Mon, 03 Jul 2023 | AU$142.7b | AU$18.1b | AU$2.3b | 37.8x | 61.2x | 7.9x |
| Wed, 31 May 2023 | AU$157.5b | AU$18.4b | AU$2.4b | 40.3x | 66.1x | 8.6x |
| Fri, 28 Apr 2023 | AU$155.5b | AU$18.2b | AU$2.3b | 41.8x | 66.3x | 8.6x |
| Sun, 26 Mar 2023 | AU$146.9b | AU$18.1b | AU$2.3b | 39.3x | 62.7x | 8.1x |
| Tue, 21 Feb 2023 | AU$151.8b | AU$17.2b | AU$2.3b | 51.3x | 66.7x | 8.8x |
| Thu, 19 Jan 2023 | AU$149.8b | AU$15.3b | AU$2.4b | 53.5x | 61.7x | 9.8x |
| Sat, 17 Dec 2022 | AU$149.0b | AU$16.1b | AU$2.6b | 46.8x | 58.1x | 9.3x |
| Mon, 14 Nov 2022 | AU$149.4b | AU$16.1b | AU$2.6b | 45.4x | 58.5x | 9.3x |
| Wed, 12 Oct 2022 | AU$144.0b | AU$17.1b | AU$2.8b | 40.6x | 52.2x | 8.4x |
| Fri, 09 Sep 2022 | AU$152.5b | AU$16.0b | AU$2.5b | 46.5x | 59.8x | 9.5x |
| Sun, 07 Aug 2022 | AU$151.3b | AU$15.6b | AU$2.8b | 41.4x | 53.6x | 9.7x |
| Tue, 05 Jul 2022 | AU$138.8b | AU$15.9b | AU$2.9b | 35.6x | 48.3x | 8.7x |
| Thu, 02 Jun 2022 | AU$138.4b | AU$15.1b | AU$2.7b | 36.5x | 51.2x | 9.2x |
Price to Earnings Ratio
51.2x
Current Industry PE
- Investors are pessimistic on the Australian Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 34.5x which is lower than its 3-year average PE of 50.2x.
- The 3-year average PS ratio of 7.4x is higher than the industry's current PS ratio of 5.4x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have grown 13% per year over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Australian Biotech compare with similar industries?
| AU Market | 0.14% | |
| Healthcare | 0.95% | |
| Biotech | 1.45% | |
| Biotech | 1.45% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CSL CSL | AU$246.38 | 1.9% +AU$2.2b | -12.3% | PE28.2x | |
| DXB Dimerix | AU$0.61 | 2.5% +AU$10.1m | 79.4% | PS480.3x | |
| ARX Aroa Biosurgery | AU$0.45 | 2.3% +AU$3.4m | -8.2% | PS2.2x | |
| OCC Orthocell | AU$1.29 | 0.8% +AU$2.4m | 238.2% | PS49.2x | |
| COV Cleo Diagnostics | AU$0.38 | 4.2% +AU$1.9m | 120.6% | PS228.6x |
